AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32965655
Drug: Foam vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam vehicle applied twice weekly for up to 52 weeks (control)
Trial: 32965655
Drug: Cal/BD foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD foam (rescue therapy) applied once daily for 4 weeks on active areas
Trial: 32965655
Drug: Cal/BD foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD foam applied twice weekly
Trial: 32965655
Drug: Foam vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam vehicle applied twice weekly (control)
Trial: 33423549
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy
Trial: 35135323
Drug: Second cohort
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second cohort (endovascular treatment)
Trial: 34487920
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 10 J/cm2 plus conventional treatment
Trial: 34487920
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 8 J/cm2 plus conventional treatment
Trial: 34487920
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 4 J/cm2 plus conventional treatment
Trial: 34487920
Drug: Placebo LLLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LLLT plus conventional treatment
Trial: 32323191
Drug: Rivaroxaban (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (twice-daily dosing)
Trial: 34559101
Drug: Yijinjing exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yijinjing exercise for 4 months in addition to conventional treatment
Trial: 34559101
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with maintained current lifestyle
Trial: 32005308
Drug: High-dose aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aminoglycoside group (≥75 mg/kg/week)
Trial: 33301738
Drug: Oral panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral panobinostat 20 mg three times weekly
Trial: 33301738
Drug: Oral panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral panobinostat 20 mg twice weekly
Trial: 33301738
Drug: Oral panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral panobinostat 10 mg three times weekly
Trial: 36207474
Drug: AI/ML-based CAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI/ML-based CAD devices for detection of colorectal polyps
Trial: 36207474
Drug: Standalone software
RxNorm normalized name: sandalore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standalone software testing for AI/ML-based CAD devices
Trial: 36268789
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg (maximum of 5 mg) of dexamethasone diluted to a total volume of 2 ml with 0.9% saline (n = 50)
Trial: 36268789
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 0.9% saline (n = 50)
Trial: 36268789
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg (maximum of 5 mg) of dexamethasone
Trial: 33151802
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow aspirate concentrate injections via superolateral, anteromedial or anterolateral portals
Trial: 33548338
Drug: Elevated or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated or increasing neutrophil count after induction chemotherapy
Trial: 34688915
Drug: Individualized Postural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized Postural Therapy (IPT)
Trial: 33558215
Drug: Rectal and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal and axillary temperature measurements
Trial: 35331432
Drug: Vein of
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein of Marshall ethanol infusion (VOMEt) as first step preceding RF ablation (VOMFIRST group)
Trial: 34781656
Drug: Subcutaneous Pegylated
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Pegylated erythropoietin at a dose of 0.6 mcg/kg body weight, once every two weeks along with intravenous iron 100 mg/week for 3 months.
Trial: 34781656
Drug: Subcutaneous darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous darbepoetin alfa at a dose of 0.45 mcg/kg body weight once weekly along with intravenous iron 100 mg/week for 3 months.
Trial: 34114138
Drug: Brinzolamide-brimonidine fixed
RxNorm normalized name: brimonidine / brinzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide-brimonidine fixed combination (1 drop, instilled 2 hours before injection)
Trial: 34114138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic medication)
Trial: 33690610
Drug: Standard nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard nevirapine syrup
Trial: 32501994
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (heat-clearing and detoxifying Chinese medicines combined with conventional therapy)
Trial: 32501994
Drug: Jinlianqingre effervescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinlianqingre effervescent tablets (part of combination therapy)
Trial: 37079268
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group (App + usual care)
Trial: 32346959
Drug: TAZ/BM cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAZ/BM cream
Trial: 32346959
Drug: TAZ gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAZ gel
Trial: 32346959
Drug: BM cream
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BM cream
Trial: 35092347
Drug: Amlodipine and
RxNorm normalized name: amlodipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine and chelation therapy
Trial: 35092347
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy only
Trial: 34919248
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline solution (NSS)
Trial: 35979636
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin
Trial: 32247530
Drug: Mindfulness and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness and self-care program consisting of 9 weekly sessions of 90min, daily practice, and reinforcement sessions at 1 month, 3, 6, and 12 months.
Trial: 34418414
Drug: Incremental hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incremental hemodialysis (twice‐weekly sessions, upwardly adjusting hemodialysis dose)
Trial: 34418414
Drug: Standard hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hemodialysis (thrice weekly for 3.5‐4 hours, minimum Dialysis Std Kt/V of 2)
Trial: 35149233
Drug: Trofinetide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trofinetide (200 mg/kg twice daily)
Trial: 35149233
Drug: Trofinetide (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trofinetide (50, 100, and 200 mg/kg BID)
Trial: 35705139
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg orally per day for 12 weeks)
Trial: 32658830
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus treatment as usual (TAU)
Trial: 36928238
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation (PMR) plus treatment as usual (TAU)
Trial: 33524060
Drug: aboBoNT‐A (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aboBoNT‐A (500 U in a 2‐mL injection volume)
Trial: 32186940
Drug: IVC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVC injection 3 to 5 days before surgery (Group 1)
Trial: 32186940
Drug: IVC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVC injection at the end of surgery (Group 2)
Trial: 32186940
Drug: IVC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVC injection 3 to 5 days before and at the end of operation (Group 3)
Trial: 35964868
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure for Primary Care (PE-PC) treatment
Trial: 33982219
Drug: TFES +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFES + biofeedback therapy
Trial: 36508996
Drug: Xanthohumol (Xn)
RxNorm normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthohumol (Xn) at a daily dose of 4.5 mg/kg body weight for 7 days
Trial: 35939810
Drug: Ensovibep (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensovibep (600 mg intravenous)
Trial: 32569258
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for PID (current national treatment guidelines)
Trial: 33507248
Drug: Mifepristone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (50 mg every 6 h for 9 days)
Trial: 34955488
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy without endovascular therapy
Trial: 35942813
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 mcg OD)
Trial: 36076231
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy Skills Intervention (CBTSI)
Trial: 35270556
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of caffeine (CAF-3)
Trial: 35270556
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg of caffeine (CAF-6)
Trial: 32299437
Drug: Projected daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Projected daily capacity for screening
Trial: 34392411
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU of daily vitamin D3
Trial: 34392411
Drug: 4000 IU
RxNorm normalized name: Cholecalciferol 4000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 IU of daily vitamin D3
Trial: 32718193
Drug: Budesonide/formoterol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol as maintenance and reliever therapy
Trial: 32953229
Drug: C1INH (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1INH (SC) 40 or 60 IU/kg twice weekly for 52-140 weeks
Trial: 33792003
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered heparin
Trial: 33792003
Drug: Control ointment
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control ointment (dexpanthenol)
Trial: 35108780
Drug: Low-flow anesthesia
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow anesthesia (1 L/min)
Trial: 35108780
Drug: High-flow anesthesia
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow anesthesia (2 L/min)
Trial: 33788459
Drug: Long-snake moxibustion
RxNorm normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-snake moxibustion combined with western medication (loperamide hydrochloride and bacillus licheniformis)
Trial: 33788459
Drug: Simple medication
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple medication (loperamide hydrochloride and bacillus licheniformis)
Trial: 32757577
Drug: Integrated Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Intervention for Dual Problems and Early Action (IIDEA), a 10-session manualized intervention that includes cognitive therapy and mindfulness practice.
Trial: 32757577
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (usual treatment plus scheduled assessments)
Trial: 33591618
Drug: semaglutide 0.25
RxNorm normalized name: SEMAGLUTIDE 0.25MG/0.375ML INJ PEN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 0.25 mg
Trial: 36184780
Drug: dulaglutide 0.75
RxNorm normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dulaglutide 0.75 mg
Trial: 36153634
Drug: Online Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Cognitive Behavioral Therapy for Insomnia (OCBT-I) + Positive Airway Pressure (PAP) therapy
Trial: 36153634
Drug: Therapist-delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-delivered Cognitive Behavioral Therapy for Insomnia (TCBT-I)
Trial: 33742252
Drug: Carboxy therapy
RxNorm normalized name: α-carboxy-3-thienylmethylpenicillin
DrugBank: Ticarcillin (DB01607)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carboxy therapy
Trial: 34063068
Drug: NATUREN G®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NATUREN G® (synbiotic formulation)
Trial: 32639946
Drug: Survival nomogram
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survival nomogram based on five clinicopathological features (race, AJCC stage, surgery for primary site, chemotherapy, tumor size)
Trial: 36351326
Drug: Early time-restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early time-restricted eating (eTRE) with a daily 6-hour eating window
Trial: 36351326
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CON) with a daily 16-hour eating window
Trial: 33516458
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (n = 36)
Trial: 33516458
Drug: Treatment waiting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment waiting list (n = 30)
Trial: 33038066
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium meal (HSM; 1,495 mg Na+)
Trial: 33038066
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium meal (LSM; 138 mg Na+)
Trial: 36367444
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of habitat manipulation and permanent change (habitat modification)
Trial: 36367444
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of manipulation and modification with larviciding
Trial: 33839747
Drug: Pretransplant bridging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretransplant bridging therapy
Trial: 33839747
Drug: Controlled disease
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled disease (under bridging therapy)
Trial: 32317673
Drug: Cadmium concentration
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadmium concentration in plants (0, 10, and 100 mg kg‐1 soil)
Trial: 32317673
Drug: Mercury concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mercury concentration in plants (0, 2, and 20 mg kg‐1 soil)
Trial: 35840747
Drug: Low-dose PTCy-ATG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PTCy-ATG (20 mg/kg on day +3 and +4, 6 mg/kg ATG)
Trial: 34530679
Drug: Developmentally adapted
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmentally adapted cognitive processing therapy (D‐CPT)
Trial: 32918100
Drug: Wait-list with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list with treatment advice (WL/TA)
Trial: 33155236
Drug: Individualized antiplatelet
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized antiplatelet therapy based on CYP2C19 genotype and platelet function (IA group)
Trial: 36060969
Drug: MET plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET plus LIRA therapy
Trial: 36060969
Drug: MET monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET monotherapy
Trial: 33269975
Drug: Nomegestrol acetate
RxNorm normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Nomegestrol acetate (NOMAc) 10 mg/day and transdermal 17-beta-estradiol (E2) 75 µg/week
Trial: 35109837
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of tranexamic acid (TXA)
Trial: 39661358
Drug: Guselkumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab treatment
Trial: 32072618
Drug: No information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No information on medication's efficacy or safety profile
Trial: 35101419
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin (target INR 2.0 to 2.5)
Trial: 35101419
Drug: Standard-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose warfarin (target INR 2.5 to 3.5)
Trial: 32919056
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (5-6 times weekly for 60 days)
Trial: 33397457
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus 1000 mg of nitazoxanide twice daily and 300/100 mg of atazanavir/ritonavir once daily orally
Trial: 33654379
Drug: Combination analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination analgesia (oral celebrex, pregabalin, and subcutaneous infiltration of ropivacaine)
Trial: 33654379
Drug: Ropivacaine (only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (only subcutaneous infiltration of ropivacaine)
Trial: 36288594
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of dexamethasone
Trial: 32533792
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and etodolac (COX2-inhibitor) administered for 20 perioperative days, starting 5 days before surgery.
Trial: 32533792
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and etodolac (treatment group).
Trial: 32533792
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and etodolac (treatment group, protocol-compliant patients).
Trial: 33543655
Drug: Melatonin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (18 mg/day) from 1 week before until 1 month after adjuvant radiotherapy
Trial: 34491543
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite infusion for 1 hour
Trial: 34491543
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion for 1 hour
Trial: 35010998
Drug: Dihydroberberine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroberberine 100 mg (D100)